Eliyahu Sharon Kalif - 13 Feb 2024 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: EVP, Chief Financial Officer
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eliyahu Sharon Kalif
Issuer symbol: TEVA
Transactions as of: 13 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 15 Feb 2024, 07:37:12 UTC
Previous filing: 01 Feb 2024
Next filing: 01 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TEVA	Ordinary Shares	Options Exercise		+6,630	+6.7%		105,792	13 Feb 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Options Exercise	$0	-6,630	-100%	$0.000000^*	0	13 Feb 2024	Ordinary Shares	6,630		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3	Restricted share units were granted on February 13, 2020, with 6,629 vesting on each of February 13, 2022, and February 13, 2023, and 6,630 vesting on February 13, 2024.